TelconRF Pharmaceutical Announces Phase 3 Clinical Trial Results of US Humanigen's COVID-19 Treatment... Both Efficacy and Safety Rated 'Excellent'

[Asia Economy Reporter Hyunseok Yoo] Humanigen, an affiliate of KPM Tech and Telcon RF Pharmaceutical, announced the results of the Phase 3 clinical trial of its COVID-19 treatment under development.

On the 29th (local time in the U.S.), Humanigen revealed that the Phase 3 clinical trial results of Lenzilumab for COVID-19 treatment showed a 54% better relative survival rate without invasive mechanical ventilation (IMV) compared to the placebo group. Not only were the results high, but they were also statistically significant.

Cameron Durrant, CEO of Humanigen, stated, “The next step is to apply for Emergency Use Authorization (EUA) from the U.S. FDA as soon as possible,” adding, “We will share these clinical results with U.S. government agencies and related organizations worldwide.”

The Phase 3 results showed that Lenzilumab had a higher survival rate compared to the placebo group, which was administered the already approved COVID-19 treatments dexamethasone and Remdesivir. In the Kaplan-Meier survival analysis, Lenzilumab showed 15.6%, while the placebo group showed 22.1%. This indicates a 54% improvement in survival without IMV.

Notably, this clinical trial produced meaningful results from tests conducted on diverse individuals with comorbidities. The finding that there is no racial difference in the use of Lenzilumab is expected to be favorable news for KPM Tech and Telcon RF Pharmaceutical.

In November last year, KPM Tech and Telcon RF Pharmaceutical secured the domestic and Philippine distribution rights for Lenzilumab from Humanigen. A KPM Tech official said, “The clinical trial principal investigator, Dr. Zelalem Temesgen, strongly suggested that Lenzilumab improves COVID-19 symptoms, reflecting very positive results,” and added, “If approved by the U.S. FDA as a COVID-19 treatment, domestic sales are also expected to gain momentum.”